<?xml version='1.0' encoding='utf-8'?>
<document id="25488594"><sentence text="Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir."><entity charOffset="107-117" id="DDI-PubMed.25488594.s1.e0" text="danoprevir" /></sentence><sentence text="Understanding transmembrane transport provides a more complete understanding of the pharmacokinetics of a drug and mechanistic explanations for drug-drug interactions" /><sentence text=" Here, the transmembrane transport of danoprevir (hepatitis C virus protease inhibitor) and the effects of ritonavir and ciclosporin on transmembrane transport of danoprevir were evaluated and clinical pharmacokinetic studies of danoprevir co-administered with/without ritonavir and ciclosporin were conducted"><entity charOffset="38-48" id="DDI-PubMed.25488594.s3.e0" text="danoprevir" /><entity charOffset="107-116" id="DDI-PubMed.25488594.s3.e1" text="ritonavir" /><entity charOffset="121-132" id="DDI-PubMed.25488594.s3.e2" text="ciclosporin" /><entity charOffset="163-173" id="DDI-PubMed.25488594.s3.e3" text="danoprevir" /><entity charOffset="229-239" id="DDI-PubMed.25488594.s3.e4" text="danoprevir" /><entity charOffset="269-278" id="DDI-PubMed.25488594.s3.e5" text="ritonavir" /><entity charOffset="283-294" id="DDI-PubMed.25488594.s3.e6" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e0" e2="DDI-PubMed.25488594.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e1" e2="DDI-PubMed.25488594.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e2" e2="DDI-PubMed.25488594.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e2" e2="DDI-PubMed.25488594.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e2" e2="DDI-PubMed.25488594.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e2" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e2" e2="DDI-PubMed.25488594.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e3" e2="DDI-PubMed.25488594.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e3" e2="DDI-PubMed.25488594.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e3" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e3" e2="DDI-PubMed.25488594.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e4" e2="DDI-PubMed.25488594.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e4" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e4" e2="DDI-PubMed.25488594.s3.e6" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e5" e2="DDI-PubMed.25488594.s3.e5" /><pair ddi="false" e1="DDI-PubMed.25488594.s3.e5" e2="DDI-PubMed.25488594.s3.e6" /></sentence><sentence text="" /><sentence text="Transcellular transport of danoprevir was evaluated in Lewis lung cancer porcine kidney, Madin-Darby canine kidney, or Chinese hamster ovary cells transfected with human transport proteins, and in human hepatocytes"><entity charOffset="27-37" id="DDI-PubMed.25488594.s5.e0" text="danoprevir" /></sentence><sentence text=" The pharmacokinetics of intravenous and oral danoprevir administered with/without ritonavir, and the impact of ciclosporin on danoprevir pharmacokinetics were evaluated in randomized, open-label, crossover studies in healthy subjects"><entity charOffset="46-56" id="DDI-PubMed.25488594.s6.e0" text="danoprevir" /><entity charOffset="83-92" id="DDI-PubMed.25488594.s6.e1" text="ritonavir" /><entity charOffset="112-123" id="DDI-PubMed.25488594.s6.e2" text="ciclosporin" /><entity charOffset="127-137" id="DDI-PubMed.25488594.s6.e3" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e0" e2="DDI-PubMed.25488594.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e0" e2="DDI-PubMed.25488594.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e0" e2="DDI-PubMed.25488594.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e0" e2="DDI-PubMed.25488594.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e1" e2="DDI-PubMed.25488594.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e1" e2="DDI-PubMed.25488594.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e1" e2="DDI-PubMed.25488594.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e2" e2="DDI-PubMed.25488594.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s6.e2" e2="DDI-PubMed.25488594.s6.e3" /></sentence><sentence text="" /><sentence text="Danoprevir transport in vitro involved organic anion transporting polypeptide (OATP) 1B1, OATP1B3, P-glycoprotein, and multidrug resistance protein-2, but not breast cancer resistance protein"><entity charOffset="0-10" id="DDI-PubMed.25488594.s8.e0" text="Danoprevir" /></sentence><sentence text=" Ritonavir and ciclosporin inhibited transport of danoprevir by human hepatocytes"><entity charOffset="1-10" id="DDI-PubMed.25488594.s9.e0" text="Ritonavir" /><entity charOffset="15-26" id="DDI-PubMed.25488594.s9.e1" text="ciclosporin" /><entity charOffset="50-60" id="DDI-PubMed.25488594.s9.e2" text="danoprevir" /><pair ddi="false" e1="DDI-PubMed.25488594.s9.e0" e2="DDI-PubMed.25488594.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s9.e0" e2="DDI-PubMed.25488594.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s9.e0" e2="DDI-PubMed.25488594.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s9.e1" e2="DDI-PubMed.25488594.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s9.e1" e2="DDI-PubMed.25488594.s9.e2" /></sentence><sentence text=" The pharmacokinetics of intravenous danoprevir 6 mg were not altered by oral ritonavir 100 mg"><entity charOffset="37-47" id="DDI-PubMed.25488594.s10.e0" text="danoprevir" /><entity charOffset="78-87" id="DDI-PubMed.25488594.s10.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25488594.s10.e0" e2="DDI-PubMed.25488594.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s10.e0" e2="DDI-PubMed.25488594.s10.e1" /></sentence><sentence text=" In contrast, exposure to oral danoprevir 100 mg increased two- to threefold when co-administered with ritonavir"><entity charOffset="31-41" id="DDI-PubMed.25488594.s11.e0" text="danoprevir" /><entity charOffset="103-112" id="DDI-PubMed.25488594.s11.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25488594.s11.e0" e2="DDI-PubMed.25488594.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s11.e0" e2="DDI-PubMed.25488594.s11.e1" /></sentence><sentence text=" Absolute bioavailability of danoprevir 100 mg was low (1"><entity charOffset="29-39" id="DDI-PubMed.25488594.s12.e0" text="danoprevir" /></sentence><sentence text="15%), but increased more than threefold (3" /><sentence text="86%) when co-administered with ritonavir"><entity charOffset="31-40" id="DDI-PubMed.25488594.s14.e0" text="ritonavir" /></sentence><sentence text=" Oral ciclosporin 100 mg increased exposure to intravenous danoprevir 2 mg and oral ritonavir 100 mg"><entity charOffset="6-17" id="DDI-PubMed.25488594.s15.e0" text="ciclosporin" /><entity charOffset="59-69" id="DDI-PubMed.25488594.s15.e1" text="danoprevir" /><entity charOffset="84-93" id="DDI-PubMed.25488594.s15.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25488594.s15.e0" e2="DDI-PubMed.25488594.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s15.e0" e2="DDI-PubMed.25488594.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s15.e0" e2="DDI-PubMed.25488594.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s15.e1" e2="DDI-PubMed.25488594.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s15.e1" e2="DDI-PubMed.25488594.s15.e2" /></sentence><sentence text="" /><sentence text="Collectively, these studies provide insight into the transmembrane transport and pharmacokinetics of danoprevir and the mechanisms that underlie a recently reported, three-way drug-drug interaction involving danoprevir, ritonavir, and ciclosporin"><entity charOffset="101-111" id="DDI-PubMed.25488594.s17.e0" text="danoprevir" /><entity charOffset="208-218" id="DDI-PubMed.25488594.s17.e1" text="danoprevir" /><entity charOffset="220-229" id="DDI-PubMed.25488594.s17.e2" text="ritonavir" /><entity charOffset="235-246" id="DDI-PubMed.25488594.s17.e3" text="ciclosporin" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e0" e2="DDI-PubMed.25488594.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e0" e2="DDI-PubMed.25488594.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e0" e2="DDI-PubMed.25488594.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e0" e2="DDI-PubMed.25488594.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e1" e2="DDI-PubMed.25488594.s17.e1" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e1" e2="DDI-PubMed.25488594.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e1" e2="DDI-PubMed.25488594.s17.e3" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e2" e2="DDI-PubMed.25488594.s17.e2" /><pair ddi="false" e1="DDI-PubMed.25488594.s17.e2" e2="DDI-PubMed.25488594.s17.e3" /></sentence><sentence text="" /></document>